Johnson & Johnson Reports TREMFYA Delivers Sustained Joint Protection And Significant Symptom Improvement Through 48 Weeks In Phase 3b Psoriatic Arthritis Study

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety profile 

More than half of TREMFYA®-treated patients across both dose groups achieved a 50% improvement in signs and symptoms of psoriatic arthritis by Week 48 in the Phase 3b APEX study 

NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.

At Week 24, TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo with results consistent for patients with active PsA receiving TREMFYA® every four weeks (Q4W)a or every eight weeks (Q8W), as assessed by the PsA-modified van der Heijde-Sharp (vdH-S) score.2 The inhibition of structural joint damage was sustained through Week 48.1 The 24 Week data from the APEX study was recently published in the Annals of the Rheumatic Diseases.3

Additionally, for patients in the study's placebo group, who switched to TREMFYA® at Week 24, the rate of radiographic progression from baseline to Week 24 (0.96) was reduced by 57% (to 0.41) from Week 24 through Week 48, as measured by mean change in the PsA-modified vdH-S score.b